Market Movers
Pre-Market and After Hours Market Movers
-
Stock Market Today: Dow Pushes Higher as Tech Stumbles and Fed Cut Bets Take Center Stage
US stocks were mixed on Tuesday as Wall Street digested fresh retail and inflation data ahead of next month’s highly…
Read More » -
Kaltura Goes All-In on Avatars & AI — Will eSelf Make or Break Them?
Kaltura is making waves after agreeing to buy eSelf.ai for $27M, a move that accelerates its shift from video SaaS…
Read More » -
Alphabet’s Race Toward a $4 Trillion Valuation Signals a New Phase of AI Dominance
Alphabet is approaching a $4 trillion market value after a recent surge that reshaped investor expectations for the future of…
Read More » -
Pacira BioSciences Pops As Activist Investor Calls For Sale — What You Need To Know!
Pacira jumped into M&A chatter after investor DOMA Perpetual urged a full sale, arguing the biotech could fetch $66/share. Activist…
Read More » -
Stock Market Today: Nasdaq, S&P 500 Rally as Nvidia, Tesla, and Google Power Big Tech Comeback
Nasdaq, S&P 500 Rally as Nvidia, Tesla, and Google Power Big Tech Comeback
Read More » -
Braskem Shares Soar: Could This Be the Comeback Moment for the Debt-Laden Giant?
Braskem jumped after a $230M settlement eased major legal risk and reports of IG4 Capital seeking control sparked hopes for…
Read More » -
Exodus Just Bought Grateful—Here’s How It Could Disrupt Stablecoin Payments
Exodus’ acquisition of Grateful adds stablecoin payments, merchant tools, and global expansion potential, helping the company move toward a broader…
Read More » -
Avadel Stock Soars As Lundbeck Outbids Alkermes—Will A Bidding War Break Out?
Lundbeck’s higher $23 bid lifts Avadel’s near-term upside and sparks talk of a bidding war, but its non-binding terms, CVR…
Read More » -
TreeHouse Foods Just Scored A Major Deal—But Is It Worth $2.9 Billion?
Investindustrial’s bid sent TreeHouse Foods soaring as the PE firm targets its margin-expansion plan, private-label growth, strong cash flow, and…
Read More » -
Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?
Intellia plunged after a patient died in its ATTR trial, prompting FDA holds on two Phase III studies and raising…
Read More »
